Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 6/20 | 0.79 |
| ▸ | INSR | P06213 | 4/20 | 0.72 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.66 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.66 |
| ▸ | BRAF | P15056 | 1/20 | 0.64 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897378 | 1.00 | IGF1R (0.79) | IGF1RINSRHSPD1HSPE1BRAF | |
| SCHEMBL15347296 | 0.88 | IGF1R (1.00) | IGF1RINSRPIK3CGPIK3CARXRA | |
| SCHEMBL15347294 | 0.88 | IGF1R (1.00) | IGF1RINSRPIK3CGPIK3CARXRA | |
| SCHEMBL6389114 | 0.87 | PIK3CG (0.79) | IGF1RINSRHSPD1HSPE1PIK3CG | |
| SCHEMBL3904132 | 0.87 | IGF1R (0.72) | IGF1RINSRHSPD1HSPE1PIK3CG | |
| SCHEMBL3904208 | 0.87 | IGF1R (0.79) | IGF1RINSRHSPD1HSPE1PIK3CG | |
| SCHEMBL3904134 | 0.87 | IGF1R (0.72) | IGF1RINSRHSPD1HSPE1PIK3CG | |
| SCHEMBL6089724 | 0.87 | IGF1R (0.72) | IGF1RINSRHSPD1HSPE1PIK3CG | |
| SCHEMBL13388762 | 0.87 | IGF1R (0.72) | IGF1RINSRHSPD1HSPE1PIK3CG | |
| SCHEMBL3904205 | 0.87 | IGF1R (0.79) | IGF1RINSRHSPD1HSPE1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | IGF1R 1698/4885INSR 2538/4885HSPD1 1909/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | IGF1R 3619/4885INSR 4203/4885HSPD1 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.